Bone Morphogenetic Protein Market

Executive Summary

Bone Morphogenetic Protein Market was valued at US $523.77 million in 2021 and is projected to grow at 5.15% CAGR over the forecast period to reach US $708.13 million by 2027. Bone Morphogenetic Protein Market represented US $50.09 million opportunity over 2019-2021 and estimated to create US $184.36 million opportunity in 2027 over 2021.

Bone Morphogenetic Protein from Consainsights analyses the Bone Morphogenetic Protein Market in the Life Sciences industry over the forecast period to 2027.

Bone Morphogenetic Protein research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Bone Morphogenetic Protein segmentation includes Type, Application and Geography.

Based on the Type, the Bone Morphogenetic Protein analysis covers Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7.

In Type segment, Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2 segment has highest cagr growth of 4.57%.

Based on the Application, the Bone Morphogenetic Protein analysis covers Spinal Fusion, Trauma, Reconstructive Surgery, Oral-maxillofacial.

In Application segment, Spinal Fusion segment has highest cagr growth of 4.57%.

Based on the region, the Bone Morphogenetic Protein analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Johnson & Johnson, Ember therapeutics Inc., Integra Lifesciences Holdings Corporation, Medtronic PLC, Bio-Techne (R&D Systems, Inc.), Merck KGaA, Pfizer, Inc., Stryker Corporation, Thermo Fischer Scientific, Zimmer Biomet Holdings, Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2 segment has the highest revenue of US $383.09 million and is expected to grow at CAGR of 4.57% by 2027 Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2 segment has highest cagr growth of 4.57%.

Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2

Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2 segment was valued at US $346.45 million in 2019 and is projected to grow at 4.57% CAGR over the forecast period to reach US $517.93 million by 2027. Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2 segment represented US $36.64 million opportunity over 2019-2021 and estimated to create US $134.84 million opportunity in 2027 over 2021.

Recombinant Human Bone Morphogenetic Protein (rhBMP) -7

Recombinant Human Bone Morphogenetic Protein (rhBMP) -7 segment was valued at US $127.23 million in 2019 and is projected to grow at 4.57% CAGR over the forecast period to reach US $190.20 million by 2027. Recombinant Human Bone Morphogenetic Protein (rhBMP) -7 segment represented US $13.45 million opportunity over 2019-2021 and estimated to create US $49.52 million opportunity in 2027 over 2021.

Application

Introduction

In 2021, Spinal Fusion segment has the highest revenue of US $238.94 million and is expected to grow at CAGR of 4.57% by 2027 Spinal Fusion segment has highest cagr growth of 4.57%.

Spinal Fusion

Spinal Fusion segment was valued at US $216.09 million in 2019 and is projected to grow at 4.57% CAGR over the forecast period to reach US $323.04 million by 2027. Spinal Fusion segment represented US $22.85 million opportunity over 2019-2021 and estimated to create US $84.10 million opportunity in 2027 over 2021.

Trauma

Trauma segment was valued at US $143.95 million in 2019 and is projected to grow at 4.57% CAGR over the forecast period to reach US $215.20 million by 2027. Trauma segment represented US $15.22 million opportunity over 2019-2021 and estimated to create US $56.02 million opportunity in 2027 over 2021.

Reconstructive Surgery

Reconstructive Surgery segment was valued at US $65.00 million in 2019 and is projected to grow at 4.57% CAGR over the forecast period to reach US $97.17 million by 2027. Reconstructive Surgery segment represented US $6.87 million opportunity over 2019-2021 and estimated to create US $25.30 million opportunity in 2027 over 2021.

Oral-maxillofacial

Oral-maxillofacial segment was valued at US $48.64 million in 2019 and is projected to grow at 4.57% CAGR over the forecast period to reach US $72.72 million by 2027. Oral-maxillofacial segment represented US $5.14 million opportunity over 2019-2021 and estimated to create US $18.93 million opportunity in 2027 over 2021.